Some users experience side-effects such as nausea, diarrhoea and fatigue. Other clinical studies have found that some patients taking weight-loss drugs lose muscle at far faster rates than those ...

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

As the ‘miracle’ drugs sweep the globe, pubs, bars and drinks manufacturers are scrambling to cope with an unexpected side ...

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

CagriSema could still be a commercial success, though ... For one, semaglutide, the active ingredient in Wegovy, is being investigated in other areas with high unmet needs. Perhaps the best ...

Novo Nordisk shares (DK:NOVO.B) (NVO) rallied 4% in early Copenhagen trade. Ozempic's 33.85 billion kroner of sales compared to analyst expectations of 33.34 billion kroner, and Wegovy's 19.87 billion ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...

Thousands of people in Cayman are using ‘skinny jabs’ like Ozempic as a weight loss aid amid an obesity epidemic that is ...